Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,725 Mln
P/E Ratio
28.51
P/B Ratio
2.23
Industry P/E
--
Debt to Equity
0.63
ROE
0.08 %
ROCE
4.88 %
Div. Yield
2.8 %
Book Value
11.97
EPS
0.94
CFO
$8,639.00 Mln
EBITDA
$12,623.00 Mln
Net Profit
$5,183.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| 9.52 | -4.03 | 5.49 | 10.10 | -6.74 | -7.08 | -2.71 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Smith & Nephew SNATS - ADR
| -9.82 | 1.45 | -22.33 | -16.21 | -10.40 | 30.84 | 8.85 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.69 | 10,202.62 | 12.01 | 12.69 | |
| 72.33 | 10,025.34 | 96.83 | 2.52 | |
| 163.14 | 8,863.93 | -- | -25.23 | |
| 296.91 | 11,513.99 | 277.87 | 3.65 |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine &... ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Address: Building 5, Watford, United Kingdom, WD18 8YE Read more
CEO & Director
Dr. Deepak S. Nath Ph.D.
CEO & Director
Dr. Deepak S. Nath Ph.D.
Headquarters
Watford
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Smith & Nephew SNATS Inc - ADR stood at $ 10,354 Mln as on 31-Dec-24
The share price of Smith & Nephew SNATS Inc - ADR is $26.92 (NYSE) as of 29-Apr-2025 16:10 EDT. Smith & Nephew SNATS Inc - ADR has given a return of -6.74% in the last 3 years.
Smith & Nephew SNATS Inc - ADR has a market capitalisation of $ 11,725 Mln as on 29-Apr-2025. As per Value Research classification, it is a company.
The P/E ratio of Smith & Nephew SNATS Inc - ADR is 28.51 times as on 29-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Smith & Nephew SNATS Inc - ADR and enter the required number of quantities and click on buy to purchase the shares of Smith & Nephew SNATS Inc - ADR.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Address: Building 5, Watford, United Kingdom, WD18 8YE
The CEO & director of Dr. Deepak S. Nath Ph.D.. is Smith & Nephew SNATS Inc - ADR, and CFO & Sr. VP is Dr. Deepak S. Nath Ph.D..
There is no promoter pledging in Smith & Nephew SNATS Inc - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| Smith & Nephew SNATS Inc. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
7.86
|
|
Operating margin(%)
|
11.31
|
|
Net Margin(%)
|
7.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Smith & Nephew SNATS Inc - ADR was $0 Mln.
$0.12
(
